Monitoring after immunotherapy plus chemoradiotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of squamous cell carcinoma of the esophagus (a specific type of esophageal cancer).
- Your cancer must be at stage II or III and located in the chest area, and your doctor believes it can be completely removed with surgery.
- You must be between 18 and 75 years old and have a good performance status (you can do most daily activities with little or no help).
- You must not have had any prior cancer treatment such as chemotherapy, radiation, or surgery for this cancer.
- You must be healthy enough for surgery and meet specific blood, liver, kidney, and heart function requirements.
- Women of childbearing age must have a negative pregnancy test and use contraception during and for 3 months after treatment; men with partners of childbearing age must also use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a new drug called adebrelimab (an immunotherapy) combined with chemotherapy, endoscopy, and radiation for people with early-stage esophageal cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer without needing surgery.
This study tests whether a new immunotherapy drug (adebrelimab) given with chemotherapy before standard chemoradiation can help people with advanced esophageal cancer that can't be removed with surgery. The goal is to see if this combination is safe and effective in shrinking tumors and controlling the disease.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.